The NIH intramural research program has shifted all non-mission-critical laboratory operations to a maintenance phase in order to promote physical distancing and diminished transmission risk of COVID-19. Effective Monday, March 23, 2020, only mission-critical functions within NIH research laboratories will be supported.

Leadership

Each of the four focus areas is led by a working group, which meets regularly to identify and develop criteria, goals, and objectives and to review progress and milestones. The working groups are managed by the Foundation for the National Institutes of Health (FNIH) and report to the ACTIV Executive Committee. This committee is under the direction of the ACTIV Partnership Leadership Group that oversees and reviews the progress of ACTIV.

Executive Committee

Francis Collins, M.D., Ph.D. (Co-Chair)
Director
National Institutes of Health

Paul Stoffels, M.D. (Co-Chair)
Vice Chairman of the Executive Committee and Chief Scientific Officer
Johnson & Johnson

Gary Disbrow, Ph.D.
Acting Director
Biomedical Advanced Research and Development Authority, HHS

Mikael Dolsten, M.D., Ph.D.
Chief Scientific Officer and President, Worldwide Research, Development and Medical
Pfizer

Anthony Fauci, M.D.
Director, National Institute of Allergy and Infectious Diseases
National Institutes of Health

Gary Gibbons, M.D.
Director, National Heart, Lung, and Blood Institute
National Institutes of Health

Peter Marks, M.D., Ph.D.
Director, Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

William Pao, M.D., Ph.D.
Head of Pharma Research and Early Development (pRED)
Roche

Andrew Plump, M.D., Ph.D.
President, Research & Development
Takeda Pharmaceutical Co. Ltd.

Janet Woodcock, M.D.
Operation Warp Speed, Therapeutics

Working Groups

Working groups for each of the four focus areas will meet regularly to identify and develop criteria, goals, and objectives and to review progress and milestones.

Preclinical Working Group

Charge: Create an integrated preclinical framework to evaluate existing drugs and drug candidates that require preclinical evaluation for both repurposing and development of novel therapeutics.

Members

Peter Adams, Ph.D.
Health Scientist, Influenza Division
Biomedical Advanced Research and Development Authority, HHS

Annaliesa Anderson, Ph.D., F.A.A.M.
Vice President and Chief Scientific Officer, Bacterial Vaccines
Pfizer

James Anderson, M.D., Ph.D.
Director, Division of Program Coordination, Planning, and Strategic Initiatives
Office of the Director, NIH

Ralph Baric, Ph.D.
Professor, Deptartment of Epidemiology and Deptartment of Microbiology and Immunology
University of North Carolina

Kara Carter, Ph.D.
Executive Vice President, Infectious Disease
Evotec

Marc Charette, Ph.D.
Program Director
Division of Cardiovascular Diseases
National Heart, Lung, and Blood Institute, NIH

Tomas Cihlar, Ph.D.
Vice President and Head of Virology
Gilead Sciences, Inc.

Christine Colvis, Ph.D. (Co-Chair)
Director, Drug Development Partnership Programs
National Center for Advancing Translational Sciences, NIH

Michael Diamond, M.D., Ph.D.
The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology
Washington University School of Medicine in St. Louis

Ken Duncan, Ph.D.
Deputy Director, Discovery – Therapeutics
Bill & Melinda Gates Foundation

Prabhavathi Fernandes, Ph.D.
SAC of GARDP, Chair; National Biodefense Science Board

Joshua Fessel, M.D., Ph.D.
Program Director, Lung Vascular Biology Program
Division of Lung Disease
National Heart, Lung, and Blood Institute, NIH

Clint Florence, Ph.D.
Program Officer, Research Resource Section, OBRR, DMID
National Institute of Allergy and Infectious Diseases, NIH

Greg Gatto, Ph.D.
Drug Development Regulatory Project Leader
RTI International

Jay Grobler, Ph.D.
Executive Director, Infectious Disease and Vaccines
Merck & Co., Inc.

Nancy Haigwood, Ph.D.
Director and Professor
Oregon National Primate Research Center
Oregon Health & Science University

Judith Hewitt, Ph.D.
Deputy Director, Office of Biodefense, Research Resources and Translational Research
National Institute of Allergy and Infectious Diseases, NIH

Samantha Jonson, M.P.S.
Special Assistant to the Director
National Center for Advancing Translational Sciences, NIH

Cat Lutz, Ph.D.
Senior Director, Mouse Repository & In Vivo Pharmacology, Rare and Orphan Disease Center
The Jackson Laboratory

Frank Nestle, M.D.
Global Head of Immunology Therapeutic Research Area and Chief Scientific Officer North America
Sanofi

Elizabeth Ottinger, Ph.D.
Senior Program Manager, Division of Preclinical Innovation
National Center for Advancing Translational Sciences, NIH

David Payne, Ph.D.
Vice President & Head, Medicine Opportunities Research Unit
GlaxoSmithKline

Louise Pitt, Ph.D.
Director, Center for Aerobiological Sciences
United States Army Medical Research Institute of Infectious Diseases

Antonella (Tony) Punturieri, Ph.D., M.D.
Program Director
Division of Lung Diseases
National Heart, Lung, and Blood Institute, NIH

Srinivas Rao, D.V.M., Ph.D.
Global Head, Translational In Vivo Models Global Research Platform
Sanofi

Jay Rappaport, Ph.D.
Professor of Microbiology and Immunology
Director and Chief Academic Officer
Tulane University National Primate Research Center

Frank Stegmeier, Ph.D.
Chief Scientific Officer
KSQ Therapeutics

John Young, Ph.D. (Co-Chair)
Global Head Infectious Diseases and Vice President
Roche

Therapeutics Clinical Working Group

Charge: Prioritize therapeutic agents for testing within an adaptive master protocol strategy that will be jointly designed by the partnership and quickly launched in networks identified by the Clinical Trial Capacity Working Group.

Members

Neil Aggarwal, M.D.
Chief, Lung Biology and Disease Branch
National Heart, Lung, and Blood Institute, NIH

Samuel Bozzette, M.D., Ph.D.
Chief Medical Officer
National Center for Advancing Translational Sciences, NIH

Jeremy Brown, M.D.
Director, Office of Emergency Care Research
National Institute of Neurological Disorders and Stroke, NIH

Tim Buchman, M.D., Ph.D.
IPA Senior Advisor, Division of Research, Innovation and Ventures (DRIVe)
Biomedical Advanced Research and Development Authority, HHS

Captain Timothy Burgess, M.D., M.P.H.
Director, Infectious Diseases Clinical Research Program
Uniformed Services University of the Health Sciences

Joan Butterton, M.D.
Associate Vice President, Clinical Research, Infectious Diseases
Merck & Co. Inc.

Sylva Collins, Ph.D.
Director, Office of Biostatistics
U.S. Food and Drug Administration

Judith Currier, M.D.
Professor of Medicine
University of California Los Angeles
Division of Infectious Diseases
Chair, AIDS Clinical Trial Group (ACTG)

Angelo DeClaro, M.D.
Division Director (Acting), Division of Hematologic Malignancies 1
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Ruxandra Draghia-Akli, M.D., Ph.D.
Global Head, Global Public Health R&D
The Janssen Pharmaceutical Companies of Johnson & Johnson

Mark Eisner, M.D., M.P.H.
Senior Vice President, Global Head of Immunology, Infectious Disease, and Ophthalmology Clinical Development
Genentech

John Farley, M.D., M.P.H.
Director, Office of Infectious Diseases
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Carl Garner, M.S., Ph.D.
Vice President, Global Regulatory Affairs
Eli Lilly and Company

David Goff, M.D., Ph.D.
Director, Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute, NIH

Keith Gottesdiener, M.D.
Retired; past President and Chief Executive Officer
Rhythm

Elizabeth Higgs M.D., M.I.A., DTM&H
Global Health Science Advisor for the Division of Clinical Research
National Institute of Allergy and Infectious Diseases, NIH

Eric Hughes, M.D., Ph.D. (Co-Chair)
Global Development Unit Head, Immunology, Hepatology & Dermatology and China Region Development Head
Novartis

Walter Koroshetz, M.D.
Director
National Institute of Neurological Disorders and Stroke, NIH

Lisa LaVange, Ph.D.
Professor and Associate Chair, Department of Biostatistics
University of North Carolina Gillings School of Global Public Health

Elliot Levy, M.D.
Senior Vice President, Global Development
Amgen

John Mellors, M.D.
Distinguished Professor of Medicine, Chief of Division of Infectious Diseases
University of Pittsburgh School of Medicine

Sandeep Menon, M.D., Ph.D.
Senior Vice President and Head of Early Clinical Development
Pfizer

Naimish Patel, M.D.
Head of Global Development, Immunology and Inflammation Therapeutic Area
Sanofi Genzyme

Amanda Peppercorn, M.D.
Senior Medical Director, Infectious Disease
GlaxoSmithKline

Mike Poole, M.D., F.A.C.P.
Therapeutic Accelerator Lead
Bill & Melinda Gates Foundation

Michael Proschan, Ph.D.
Mathematical Statistician, Biostatistics Research Branch
National Institute of Allergy and Infectious Diseases, NIH

Sarah Read, M.D. (Co-Chair)
Deputy Director, Division of AIDS
National Institute of Allergy and Infectious Diseases, NIH

Lora Reineck, M.D., M.S.
Program Director, Acute Lung Injury/Critical Care Program
Division of Lung Diseases
National Heart, Lung, and Blood Institute, NIH

Yves Rosenberg, M.D., M.P.H.
Chief, Atherothrombosis and Coronary Artery Disease Branch
National Heart, Lung, and Blood Institute, NIH

Peter Stein, M.D.
Director of Office of New Drugs
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Pamela Tenaerts, M.D., M.B.A.
Executive Director, Clinical Trial Transformation Initiative
Duke University Clinical Research Institute

Peter Wung, M.D.
Associate Vice President, Global OMD Lead, Immuno-Inflammation
Sanofi

Clinical Trial Capacity Working Group

Charge: Develop a full inventory of clinical trial capacity, including networks from NIH ICs, industry, and contract research organizations (CROs), that will serve as potential settings in which to implement effective COVID-19 clinical trials.

Members

Lionel Bascles, Ph.D.
Senior Vice President, Global Head of Clinical Sciences & Operations
Sanofi

Myron Cohen, M.D.
Associate Vice Chancellor for Global Health and Medical Affairs
Yeargan-Bate Distinguished Professor of Medicine, Microbiology and Immunology, and Epidemiology
Director, Institute for Global Health & Infectious Diseases
University of North Carolina, Chapel Hill

Lawrence Corey, M.D.
Professor, Departments of Laboratory Medicine & Medicine
Member, Division of Vaccine & Infectious Disease (VIDD), Clinical Research, & Public Health Sciences
President & Director Emeritus
Fred Hutchinson Cancer Research Center

Victoria Davey, Ph.D., M.P.H.
Associate Chief Research & Development Officer, Epidemiology and Public Health
U.S. Department of Veterans Affairs

Elizabeth Desrosiers, M.S., P.M.P. (Co-Chair)
Executive Director, Clinical Sciences and Study Management
Merck & Co., Inc.

James Dickens
Program Manager, Office of Rare Diseases Research
National Center for Advancing Translational Sciences, NIH

Jim Doroshow, M.D.
Director, Division of Cancer Treatment and Diagnosis
National Cancer Institute, NIH

Carlos Garner, Ph.D.
Vice President, Global Regulatory Affairs
Eli Lilly and Company

David Goff, M.D., Ph.D.
Director, Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute, NIH

Penny Heaton, Ph.D.
Chief Executive Officer
Bill & Melinda Gates Medical Research Institute

Michael Kurilla, M.D., Ph.D. (Co-Chair)
Director, Division of Clinical Innovation
National Center for Advancing Translational Sciences, NIH

George Mensah, M.D.
Director, Center for Translation Research & Implementation Science
National Heart, Lung, and Blood Institute, NIH

Seema Nayak, M.D.
Director, Office of Clinical Research Resources
National Institute of Allergy and Infectious Diseases, NIH

Manizhe Payton, M.P.H.
Director, Office of Clinical Site Oversight, DAIDS
National Institute of Allergy and Infectious Diseases, NIH

Laura Resnansky, B.S.N.
Vice President, Global Head of Clinical Operations - Immunology, Infectious Diseases, Ophthalmology and Neuroscience
Genentech

Christine Sizemore, Ph.D.
Director, Division of International Relations
Fogarty International Center, NIH

Badhri Srinivasan, A.B.D., M.S.
Head, Global Development Operations
Novartis

Peter Stein, M.D.
Director of Office of New Drugs
Center for Drug Evaluation and Research
U.S. Food and Drug Administration

Therese Takas
Director, Clinical Operations
AstraZeneca

Mike Vincent, M.D., Ph.D.
Senior Vice President and Chief Scientific Officer of the Inflammation and Immunology Research Unit
Pfizer

Gail Weinmann, M.D.
Deputy Director, Division of Lung Diseases
National Heart, Lung, and Blood Institute, NIH

Vaccines Working Group

Charge: Accelerate evaluation of vaccine candidates by supporting harmonized clinical efficacy trials and a parallel effort to generate biomarkers and other evidence for more rapid approval/authorization.

Members

Paula Annunziato, M.D.
Vice President and Therapeutic Area Head, Vaccines Clinical Research
Merck & Co., Inc.

Ann Arvin, M.D.
Lucile Salter Packard Professor of Pediatrics and Professor of Microbiology and Immunology
Stanford University School of Medicine

Beth Bell, M.D.
Clinical Professor, Global Health
University of Washington

Susan Buchbinder, M.D.
Clinical Professor of Medicine, University of California, San Francisco
Director of HIV Prevention Research, San Francisco Department of Public Health

Marco Cavaleri, Ph.D.
Head, Biological Health Threats and Vaccines Strategy
European Medicines Agency

Lawrence Corey, M.D.
Professor, Departments of Laboratory Medicine & Medicine
Member, Division of Vaccine & Infectious Disease (VIDD), Clinical Research, & Public Health Sciences
President & Director Emeritus
Fred Hutchinson Cancer Research Center

Mark Davis, Ph.D.
Professor, Microbiology and Immunology
Director, Stanford Institute for Immunology, Transplantation and Infection
Stanford University School of Medicine

Emilio Emini, Ph.D.
Director, TB & HIV Program
Bill & Melinda Gates Foundation

Gregory Glenn, M.D.
Chief Scientific Officer
Novavax, Inc.

Emmanuel Hanon, Ph.D.
Senior Vice President of Vaccines Research and Development
GlaxoSmithKline

Barton Haynes, M.D.
Frederic M. Hanes Distinguished Professor of Medicine
Director, Duke Human Vaccine Institute
Duke University

Peter Hotez, M.D., Ph.D.
Dean, National School of Tropical Medicine
Baylor College of Medicine
Director, Center for Vaccine Development
Texas Children’s Hospital

Kathrin Jansen, Ph.D. (Co-Chair)
Senior Vice President and Head of Vaccine Research and Development
Pfizer

Antonio Lanzavecchia, M.D.
Senior Vice President and Senior Research Fellow
Vir Biotechnology, Inc.
Director, Institute for Research in Biomedicine, Bellinzona, Switzerland

Douglas Lowy, M.D. (Co-Chair)
Principal Deputy Director
National Cancer Institute, NIH

Peter Marks, M.D., Ph.D.
Director
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

John Mascola, M.D.
Director, Dale and Betty Bumpers Vaccine Research Center
National Institute of Allergy and Infectious Diseases, NIH

Nancy Messonnier, M.D.
Director, Center for the National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Nelson Michael, M.D., Ph.D.
Director, Center for Infectious Diseases Research
Walter Reed Army Institute of Research, U.S. Army Medical Research and Development Command

Paul Offit, M.D.
Director, Vaccine Education Center
Maurice R. Hilleman Professor of Vaccinology at the Perelman School of Medicine at the University of Pennsylvania
Professor, Children’s Hospital of Philadelphia

Hanneke Schuitemaker, Ph.D.
Global Head of Viral Vaccine Discovery and Translational Medicine
Johnson & Johnson
Professor in Virology at the Amsterdam University Medical Center of the University of Amsterdam

Jonathan Seals, Ph.D.
Director, Strategic Science and Technology
Biomedical Advanced Research and Development Authority, HHS

Jim Tartaglia, Ph.D.
Vice President for Research and Development
Sanofi Pasteur

Tonya Villafana, M.P.H., Ph.D.
Vice President, Global Franchise Head, Infection
AstraZeneca

Tal Zaks, M.D., Ph.D.
Chief Medical Officer
Moderna, Inc.

This page last reviewed on July 9, 2020